RGT-419B

DRUG2 trials

Sponsors

Regor Pharmaceuticals Inc.

Conditions

Advanced Solid TumorBreast Cancer

Phase 1

FIH Study of RGT-419B Alone and With Endocrine Therapy in HR-Positive, HER2-Negative Advanced/Metastatic Breast Cancer

RecruitingNCT05304962

Regor Pharmaceuticals Inc.Breast Cancer

Start: 2022-03-04End: 2027-03-31Target: 64Updated: 2026-08-12

A Phase I Study of RGT-419B in Patients With HR-Positive, HER2-Negative Advanced Breast Cancer or Other Solid Tumors

Active, not recruitingNCT06299124

Regor Pharmaceuticals Inc.Advanced Solid Tumor, Breast Cancer

Start: 2023-04-17End: 2026-12-30Target: 40Updated: 2026-08-27